CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to shareholders for the first half of the year was 946 million yuan, a year-on-year decrease of 3.43%.
China Resources Pharmaceutical (03320) announced that its subsidiary, China Resources Double-Crane, achieved total operating revenue of 5.615 billion yuan for the six months ending June 30, 2026, a decrease of 3.44% year-on-year; net profit attributable to shareholders of the listed company was 946 million yuan, down 3.43% year-on-year; basic earnings per share were 0.9163 yuan.
CHINARES PHARMA (03320) announced that its subsidiary China Resources Double-Crane Pharmaceutical achieved a total revenue of 5.615 billion yuan for the six months ending June 30, 2026, a year-on-year decrease of 3.44%; the net profit attributable to shareholders of the listed company was 946 million yuan, a year-on-year decrease of 3.43%; the basic earnings per share was 0.9163 yuan.
Related Articles
BEKE-W (02423) announced its second-quarter performance, with adjusted net profit of 3.185 billion yuan, a year-on-year increase of 74.9%.
Transformation effectiveness + stock market recovery, BEKE-W (02423) profit margin rises to 14.6%: both second-hand and new homes increase, home decoration rental controls quantity while improving quality.
Huaqin Co., Ltd. (03296) spent 29.9802 million yuan on August 21 to repurchase 384,400 A shares.
BEKE-W (02423) announced its second-quarter performance, with adjusted net profit of 3.185 billion yuan, a year-on-year increase of 74.9%.
Transformation effectiveness + stock market recovery, BEKE-W (02423) profit margin rises to 14.6%: both second-hand and new homes increase, home decoration rental controls quantity while improving quality.
Huaqin Co., Ltd. (03296) spent 29.9802 million yuan on August 21 to repurchase 384,400 A shares.
RECOMMEND
